Style | Citing Format |
---|---|
MLA | Azarfar A, et al.. "Efficacy and Safety of Rituximab in Children With Difficult-To-Treat Nephrotic Syndrome; a Systematic Review." Journal of Renal Injury Prevention, vol. 7, no. 4, 2018, pp. 307-313. |
APA | Azarfar A, Ravanshad Y, Mehradmajd H, Aval SB, Nastarani S, Emadzadeh M, Khazaei MR, Fazel M, Azimi B (2018). Efficacy and Safety of Rituximab in Children With Difficult-To-Treat Nephrotic Syndrome; a Systematic Review. Journal of Renal Injury Prevention, 7(4), 307-313. |
Chicago | Azarfar A, Ravanshad Y, Mehradmajd H, Aval SB, Nastarani S, Emadzadeh M, Khazaei MR, Fazel M, Azimi B. "Efficacy and Safety of Rituximab in Children With Difficult-To-Treat Nephrotic Syndrome; a Systematic Review." Journal of Renal Injury Prevention 7, no. 4 (2018): 307-313. |
Harvard | Azarfar A et al. (2018) 'Efficacy and Safety of Rituximab in Children With Difficult-To-Treat Nephrotic Syndrome; a Systematic Review', Journal of Renal Injury Prevention, 7(4), pp. 307-313. |
Vancouver | Azarfar A, Ravanshad Y, Mehradmajd H, Aval SB, Nastarani S, Emadzadeh M, et al.. Efficacy and Safety of Rituximab in Children With Difficult-To-Treat Nephrotic Syndrome; a Systematic Review. Journal of Renal Injury Prevention. 2018;7(4):307-313. |
BibTex | @article{ author = {Azarfar A and Ravanshad Y and Mehradmajd H and Aval SB and Nastarani S and Emadzadeh M and Khazaei MR and Fazel M and Azimi B}, title = {Efficacy and Safety of Rituximab in Children With Difficult-To-Treat Nephrotic Syndrome; a Systematic Review}, journal = {Journal of Renal Injury Prevention}, volume = {7}, number = {4}, pages = {307-313}, year = {2018} } |
RIS | TY - JOUR AU - Azarfar A AU - Ravanshad Y AU - Mehradmajd H AU - Aval SB AU - Nastarani S AU - Emadzadeh M AU - Khazaei MR AU - Fazel M AU - Azimi B TI - Efficacy and Safety of Rituximab in Children With Difficult-To-Treat Nephrotic Syndrome; a Systematic Review JO - Journal of Renal Injury Prevention VL - 7 IS - 4 SP - 307 EP - 313 PY - 2018 ER - |